Carnage in Less Invasive Diabetes Testing
This article was originally published in Start Up
Plenty of start-ups have attempted to develop less-invasive systems for diabetes testing with very little success. MiniMed Inc. appears to be the farthest along; it is awaiting FDA approval for a continuous real-time blood glucose monitor which can be implanted under the skin.
You may also be interested in...
The goals being touted in the treatment of diabetes are lofty, with the development of a functional and affordable artificial pancreas topping the list of ambitious undertakings in the industry. The pursuit of such a device has been a Holy Grail quest for some time now, and over the years the feasibility of developing a man-made mechanism to take the place of a faulty body organ has been treated with a share of optimism and skepticism. However, based on recent FDA approvals for multiple manufacturers, it appears the industry is closer than it has ever been to making this goal a reality.
Marks appeared to use the variable EUA bar to justify what many viewed as early mistakes by FDA during COVID-19, and to emphasize the importance of physician awareness of the strength of evidence used to authorize a drug.
Patent office could request information from FDA that is material to patentability, speakers at USPTO-FDA ‘listening session’ advise the agencies. Information exchange raises questions about trade secret protection and burdens on agencies.